Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed

Conditions studied: Breast Cancer

In brief

A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States

Key facts

Study ID

NCT06086340

Run by

Pfizer

People needed

779

Starts

2023-09-29

Expected to finish

2024-01-24

Last updated by the study team

2025-11-18

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• De novo metastatic (stage IV) disease at initial breast cancer diagnosis during 2015-2019
• HR+/HER2- molecular subtype at diagnosis
• Initiated 1L systemic therapy with palbociclib + AI or AI alone

You may not qualify if…

• Patients will be excluded if their metastatic breast cancer diagnosis was first recorded in a death certificate or at the time of autopsy.

Where it is running

• Pfizer New York — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.